Daily Times – Site Edition
The News Review:
- Daily Times – Site Edition
- Roche’s Investigational Hepatitis C Polymerase Inhibitor R1626…
- Three Studies Presented At 43rd EASL Showed Higher SVR For PEGASYS(R)…
Daily Times – Site Edition
Daily Times – Apr 27, 2008
Addressing a seminar on Clinical Research Management in Pakistan on Saturday she said that Pakistan has a strong reservoir of qualified personnel laboratories and hospitals to carve a niche for itself in the field. “All that is needed is to put them together and start conducting trials” she said at the event organised jointly by the Ministry of Health Jinnah Post Graduate Medical Center and the Trade Development Authority of Pakistan (TDAP). She hoped that recommendations forwarded by participants of the seminar and the workshop for local clinicians on Sunday will help in making the ongoing scattered clinical research in the country more efficient and substantial. TDAP Chief Executive Tariq Ikram said Pakistan even against the most conservative estimates can easily earn US $50000 to $100000 through clinical trials in the next few years. “rganised and concerted attempts to be in the international field will have multifold benefits including job opportunities for clinicians lab technicians etc.
Roche’s Investigational Hepatitis C Polymerase Inhibitor R1626…
Medical News Today – Apr 27, 2008
PEGASYS is dosed at 180mcg as a subcutaneous injection taken once a week. CPEGUS is available as a 200mg tablet and is administered orally two times a day as a split dose. Roche has backed PEGASYS with the most extensive clinical research program ever undertaken in hepatitis C with major studies initiated to advance treatment for hepatitis C patients with unmet needs including patients co-infected with HIV and HCV African Americans patients with cirrhosis and patients who have failed to respond to previous therapy. IMPRTANT SAFETY INFRMATIN PEGASYS alone or in combination with CPEGUS is indicated for the treatment of adults with chronic hepatitis C virus infection who have compensated liver disease and have not been previously treated with interferon alpha. Patients in whom efficacy was demonstrated included patients with compensated liver disease and histological evidence of cirrhosis (Child-Pugh class A). Alpha interferons including PEGASYS(R) (Peginterferon alfa-2a) may cause or aggravate fatal or life-threatening neuropsychiatric autoimmune ischemic and infectious disorders. Patients should be monitored closely with periodic clinical and laboratory evaluations.
Three Studies Presented At 43rd EASL Showed Higher SVR For PEGASYS(R)…
Medical News Today – Medical News Today (press release) – Apr 27, 2008
PEGASYS is dosed at 180mcg as a subcutaneous injection taken once a week. CPEGUS is available as a 200mg tablet and is administered orally two times a day as a split dose. Roche has backed PEGASYS with the most extensive clinical research program ever undertaken in hepatitis C with major studies initiated to advance treatment for hepatitis C patients with unmet needs including patients co-infected with HIV and HCV African Americans patients with cirrhosis and patients who have failed to respond to previous therapy. IMPRTANT SAFETY INFRMATIN PEGASYS alone or in combination with CPEGUS is indicated for the treatment of adults with chronic hepatitis C virus infection who have compensated liver disease and have not been previously treated with interferon alpha. Patients in whom efficacy was demonstrated included patients with compensated liver disease and histological evidence of cirrhosis (Child-Pugh class A). Alpha interferons including PEGASYS(R) (Peginterferon alfa-2a) may cause or aggravate fatal or life-threatening neuropsychiatric autoimmune ischemic and infectious disorders. Patients should be monitored closely with periodic clinical and laboratory evaluations.
Written by admin on April 27th, 2008 with
no comments.
Read more articles on News.